Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 TrialJohn Mascarenhas, Ronald Hoffman, Heidi Kosiorek et al.|Blood|2020Cited by 11
A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B-Cell Non-Hodgkin Lymphomas (NHL)Sarit Assouline, Seung‐Tae Lee, Jenny Thirlway et al.|Blood|2023Cited by 2